ResMed Inc. sees fresh institutional buying, shares hover near 200 dollars

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-27, 10:50.

ResMed Inc. (US7611521078) has drawn new institutional interest, with Banque Cantonale Vaudoise disclosing a fresh stake in the NYSE-listed medical equipment provider in its latest SEC filing. The move comes as ResMed combines double-digit revenue growth with net margins above 27 percent, according to recent data compiled by MarketBeat. MarketBeat report on Banque Cantonale Vaudoise stake

New stake from Banque Cantonale Vaudoise

MarketBeat reports that Banque Cantonale Vaudoise bought 7,693 ResMed shares in the first quarter, a new position disclosed through the US Securities and Exchange Commission. MarketBeat filing summary The stake adds another long-term investor to ResMed’s shareholder base at a time when the company’s reported market capitalization stands at about 29.08 billion dollars, based on the latest trading data. MarketBeat ResMed news and data

According to the same MarketBeat overview, ResMed shares carry a price-to-earnings ratio of 19.33 and a price-to-earnings-growth ratio of 1.27, pointing to an earnings profile that investors compare with other global medtech names such as Philips and Fisher & Paykel Healthcare in the sleep and respiratory-care segment. MarketBeat valuation metrics

Long-term profile and analyst stance

ResMed reported quarterly earnings on April 30, posting earnings per share of 2.86 dollars, seven cents above the consensus forecast of 2.79 dollars collected by analysts. MarketBeat earnings recap Revenue for the period reached 1.43 billion dollars, slightly ahead of the 1.42 billion dollars consensus and up 10.8 percent year-on-year, a pace that supports ResMed’s long-term growth narrative in sleep apnea and chronic respiratory care. MarketBeat revenue comparison

The same data set indicates that ResMed generated a net margin of 27.44 percent and a return on equity of 25.35 percent in the reported quarter, metrics that many investors view as robust for a device maker with significant software and cloud components. MarketBeat profitability metrics Analysts tracked by MarketBeat expect ResMed to deliver full-year earnings per share of 11.13 dollars, underscoring that the current valuation embeds expectations of continued margin discipline and steady growth.

The business behind the ResMed devices

ResMed generates the bulk of its revenue by supplying sleep apnea and respiratory-care devices, including continuous positive airway pressure (CPAP) machines and connected masks under brands such as AirSense and AirFit. The company also offers cloud-based monitoring platforms that help physicians and homecare providers track patient adherence and therapy effectiveness, turning its hardware installed base into a recurring software and data revenue stream. ResMed product overview

Where the ResMed shares trade today

ResMed Inc. shares (US7611521078) last closed on June 26, 2026 on the NYSE at around 200.49 dollars, with MarketBeat citing a previous close near 200.49 dollars and TradingKey reporting a comparable level around 200.29 dollars for the ResMed ticker RMD. MarketBeat ResMed quote TradingKey ResMed price snapshot The shares therefore trade almost exactly around the 200-dollar mark as of the latest closing print.

This article provides factual information on ResMed Inc. and its shares and does not contain any investment advice, recommendation or solicitation to buy or sell securities. Figures and dates are based on sources cited and may change with new disclosures or market data.